Literature DB >> 27381827

Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease.

Kinga G Blecharz1, Dietmar Frey2, Tobias Schenkel1, Vincent Prinz2, Gloria Bedini3,4, Susanne M Krug5, Marcus Czabanka2, Josephin Wagner1, Michael Fromm5, Anna Bersano6,7, Peter Vajkoczy1,2,8.   

Abstract

Moyamoya disease is a rare steno-occlusive cerebrovascular disorder often resulting in hemorrhagic and ischemic strokes. Although sharing the same ischemic stimulus with atherosclerotic cerebrovascular disease, Moyamoya disease is characterized by a highly instable cerebrovascular system which is prone to rupture due to pathological neovascularization. To understand the molecular mechanisms underlying this instability, angiopoietin-2 gene expression was analyzed in middle cerebral artery lesions obtained from Moyamoya disease and atherosclerotic cerebrovascular disease patients. Angiopoietin-2 was significantly up-regulated in Moyamoya vessels, while serum concentrations of soluble angiopoietins were not changed. For further evaluations, cerebral endothelial cells incubated with serum from these patients in vitro were applied. In contrast to atherosclerotic cerebrovascular disease serum, Moyamoya disease serum induced an angiopoietin-2 overexpression and secretion, accompanied by loss of endothelial integrity. These effects were absent or inverse in endothelial cells of non-brain origin suggesting brain endothelium specificity. The destabilizing effects on brain endothelial cells to Moyamoya disease serum were partially suppressed by the inhibition of angiopoietin-2. Our findings define brain endothelial cells as the potential source of vessel-destabilizing factors inducing the high plasticity state and disintegration in Moyamoya disease in an autocrine manner. We also provide new insights into Moyamoya disease pathophysiology that may be helpful for preventive treatment strategies in future.

Entities:  

Keywords:  Moyamoya; angiogenesis; cell culture; cerebrovascular disease; stroke

Mesh:

Substances:

Year:  2016        PMID: 27381827      PMCID: PMC5453470          DOI: 10.1177/0271678X16658301

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  41 in total

Review 1.  Clinical applications of angiogenic growth factors and their inhibitors.

Authors:  N Ferrara; K Alitalo
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Moyamoya disease: collateralization is everything.

Authors:  Peter Vajkoczy
Journal:  Cerebrovasc Dis       Date:  2009-07-14       Impact factor: 2.762

Review 3.  Vasculogenic and Angiogenic Pathways in Moyamoya Disease.

Authors:  Gloria Bedini; Kinga G Blecharz; Sara Nava; Peter Vajkoczy; Giulio Alessandri; Michela Ranieri; Francesco Acerbi; Paolo Ferroli; Daria Riva; Silvia Esposito; Chiara Pantaleoni; Nardo Nardocci; Federica Zibordi; Elisa Ciceri; Eugenio A Parati; Anna Bersano
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis.

Authors:  Kinga G Blecharz; Aiden Haghikia; Mariusz Stasiolek; Niels Kruse; Detlev Drenckhahn; Ralf Gold; Norbert Roewer; Andrew Chan; Carola Y Förster
Journal:  Mult Scler       Date:  2010-03       Impact factor: 6.312

5.  Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.

Authors:  J R Gamble; J Drew; L Trezise; A Underwood; M Parsons; L Kasminkas; J Rudge; G Yancopoulos; M A Vadas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 6.  Tight junctions in brain barriers during central nervous system inflammation.

Authors:  Caroline Coisne; Britta Engelhardt
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

7.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

8.  Adherens junctions in endothelial cells regulate vessel maintenance and angiogenesis.

Authors:  Maria Grazia Lampugnani; Elisabetta Dejana
Journal:  Thromb Res       Date:  2007       Impact factor: 3.944

9.  Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.

Authors:  S Tanaka; M Mori; Y Sakamoto; M Makuuchi; K Sugimachi; J R Wands
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 10.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

Authors:  Damien Gerald; Sudhakar Chintharlapalli; Hellmut G Augustin; Laura E Benjamin
Journal:  Cancer Res       Date:  2013-03-06       Impact factor: 12.701

View more
  11 in total

1.  Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia.

Authors:  Aiki Marushima; Melina Nieminen; Irina Kremenetskaia; Roberto Gianni-Barrera; Johannes Woitzik; Georges von Degenfeld; Andrea Banfi; Peter Vajkoczy; Nils Hecht
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

2.  Multiple protocadherins are expressed in brain microvascular endothelial cells and might play a role in tight junction protein regulation.

Authors:  Christina Dilling; Norbert Roewer; Carola Y Förster; Malgorzata Burek
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-17       Impact factor: 6.200

3.  Interleukin 6-Mediated Endothelial Barrier Disturbances Can Be Attenuated by Blockade of the IL6 Receptor Expressed in Brain Microvascular Endothelial Cells.

Authors:  Kinga G Blecharz-Lang; Josephin Wagner; Alexa Fries; Melina Nieminen-Kelhä; Jörg Rösner; Ulf C Schneider; Peter Vajkoczy
Journal:  Transl Stroke Res       Date:  2018-02-10       Impact factor: 6.829

4.  Mutations of RNF213 are responsible for sporadic cerebral cavernous malformation and lead to a mulberry-like cluster in zebrafish.

Authors:  Jing Lin; Jie Liang; Jun Wen; Man Luo; Jiaoxing Li; Xunsha Sun; Xiaowei Xu; Jianli Li; Dongxian Wang; Jie Wang; Huimin Chen; Rong Lai; Fengyin Liang; Chuan Li; Fei Ye; Jingjing Zhang; Jinsheng Zeng; Shulan Yang; Wenli Sheng
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-04       Impact factor: 6.200

Review 5.  Genetic and Proteomic Contributions to the Pathophysiology of Moyamoya Angiopathy and Related Vascular Diseases.

Authors:  Kirsten B Dorschel; John E Wanebo
Journal:  Appl Clin Genet       Date:  2021-03-18

6.  Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease.

Authors:  Kinga G Blecharz-Lang; Vincent Prinz; Małgorzata Burek; Dietmar Frey; Tobias Schenkel; Susanne M Krug; Michael Fromm; Peter Vajkoczy
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-10       Impact factor: 6.200

Review 7.  Circular RNAs and neutrophils: Key factors in tackling asymptomatic moyamoya disease.

Authors:  Sydney Corey; Yumin Luo
Journal:  Brain Circ       Date:  2019-09-30

8.  Microstructural damage pattern of vascular cognitive impairment: a comparison between moyamoya disease and cerebrovascular atherosclerotic disease.

Authors:  Jia-Bin Su; Si-Da Xi; Shu-Yi Zhou; Xin Zhang; Shen-Hong Jiang; Bin Xu; Liang Chen; Yu Lei; Chao Gao; Yu-Xiang Gu
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

9.  Significance of Serum Angiopoietin-2 in Patients with Hemorrhage in Adult-Onset Moyamoya Disease.

Authors:  Jianbo Yu; Kaiyuan Huang; Jianwei Pan; Jian Shen; Renya Zhan
Journal:  Biomed Res Int       Date:  2020-08-04       Impact factor: 3.411

Review 10.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.